Category Archives: Epigenetics

As I reflect on my childhood, knowing what I know regarding Adverse Childhood Experiences or ACEs, and my score of a three, along with a high school graduating ACT score of a 15, it would seem unusual that in my freshman year at Northern State University that I, a probationary student would end the year on the Deans Presidential Scholarship List with a 4.0 GPA.

Equally astounding, was my completion of a Master of Science in Pastoral Care and Counseling degree with a 3.9 GPA. My life goal was to become an educator to make learning enjoyable and to be kind to others in the process. A defining moment in my life was when the well-intentioned high school counselor took me aside, and gently said, You might be able to be a teachers assistant, although because of your test score, not the actual classroom teacher.

It was exactly what I needed to hear. It agitated me just enough to set my sight on my goal and nothing was going to stop me from achieving it. I graduated from the university with an elementary education degree and a special education degree (K-12).

I went on to enjoy 27 delightful years as a classroom teacher until I had the opportunity to join St. Francis Health. Now in my seventh year, this life-giving Mission and Ministry position continues to exemplify how my students and parents continue to be my best teachers.

University of Pennsylvania Psychologist, Angela Duckworth, would call this grit. She defines grit as the perseverance and passion for long term goals with no particular concern for rewards or recognition along the way. It combines resilience, ambition, and self-control in pursuit of goals that take months, years, or even decades. Her published research in the book, Grit-The Power of Passion and Perseverance, a New York Times bestseller documents how grit predicts long-term success in nearly every realm of life.

Dr. Duckworths studies began when she was teaching math to seventh graders. She realized IQ wasnt the only factor separating successful students from those who struggled. Goals through time were the highly predictive of success. In most research studies, grit and measures of talent and IQ are unrelated, suggesting that talent puts no limits on capacity for passion and perseverance.

Since we can only teach what we truly know, below is Dr. Duckworths Pulse Check to gauge your current level of grit, considering how true the following are for you:

1. I enjoy projects that take years to complete.

2. I am working towards a very long-term goal.

3. What I do each day is connected to my deepest personal values.

4. There is at least one subject or activity that I never get bored of thinking about.

5. Setbacks dont discourage me for long.

7. I finish whatever I begin.

8. I never stop working to improve.

Your disposition to pursue long-term goals with passion and perseverance like risk for heart disease, interest in art, and your intelligence is both heritable and malleable. Ninety-nine percent of your genes are the same as mine or your neighbors and literally everyone else you know. Only a tiny fraction of human genes differ. These genetic differences among people are correlated with differences in our physical and psychological characteristics.

Our genetic heritage does not have complete authority over our life destiny UNLESS we allow it. From Harvard University Center on the Developing Child epigenetics research, we know that genes make a difference AND so does experience so dont assume that nature and nurture are mutually exclusive. It also reminds us of how essential it is to look for ways to enrich the environments of the young people in our lives. Epigenetics refers to changes in which genes are expressed and how early experiences alter gene expression and shape development.

According to Dr. Ducksworths research, here are some ways to encourage grit in others:

1. Model it. If you love what you do, let others know. Wear your passion on your sleeve. When you fail, openly share your frustration yet go out of your way to point our what you learned from the experience. Emphasize playing the long game in life. Life is a marathon, rather than a sprint.

2. Celebrate it. When you see grit, draw attention to it. Your work on this project has demonstrated tremendous perseverance. I know it took a huge effort on your part. Praise passion such as: You are really in the flow with this project and Im so happy for you.

3. Enable it. The paradox of grit is that determination of individuals is made possible by warmth and support of friends, families whether biological or chosen, teachers, and mentors.

God honors a beautiful blend of gift and grit! He gives the gift and expects us to have the grit to practice and learn how to use it effectively. ~ Beth Moore

For more information on how to most effectively use behavioral science to transform peoples lives to bring out their highest good go to: bcfg.wharton.upenn.edu Creating Enduring Behavior Change or Dr. Duckworths: Characterlab.org for actionable advice for parents and teachers based on science.

Sandy Block-Hansen, MS. St. Francis Healthcare Campus Family Footprints Coordinator. A Catholic Health Initiative Mission and Ministry program created to support, inform, and offer resources to parents in the role of parenting. She can be reached at sandrablock-hansen@catholichealth.net or 218.643.0475

See the original post:
Grit is the glue in life's marathon! | Health - Wahpeton Daily News

In this Epigenetics Market Global Industry Analysis & Forecast to 2030 research report, the central factors driving the advancement of this industry were recorded and the business accessories and end overseers were indulgent. This statistical surveying Epigenetics report investigates and inspects the industry and determines a widely inclusive estimate of its development and its details. Another perspective that was efficient is the cost analysis of the prime products driving in the Epigenetics Industry remembering the overall revenue of the manufacturers.

The following key Epigenetics Market insights and pointers are covered during this report:

Request a demo sample: https://prophecymarketinsights.com/market_insight/Insight/request-sample/36

The prime manufacturers covered during this report are:

Illumina Inc., Thermo Fisher Scientific Inc., Merck Millipore Limited, Bio-Rad Laboratories, Inc., Qiagen Inc., Zymo Research Corporation, Diagenode s. a., Enzo Life Sciences, Inc. and New England Biolabs Inc.

Detail Segmentation:

Download PDF Brochure @ https://prophecymarketinsights.com/market_insight/Insight/request-sample/36

The report is an entire guide in providing complete Epigenetics processes, cost structures, raw materials, investment feasibility, and investment return analysis. The SWOT analysis, market growth, production, profit, and supply-demand statistics are offered

The historical and future trends, prices, product demand, prospects, and Epigenetics marketing channels are stated. The current business and progressions, future methodologies, market entrants are explained. The consumers, distributors, manufacturers, traders, and dealers in Business Intelligence (Bi) Software Market are covered. A comprehensive research methodology, market size estimation, market breakdown, and data triangulation is roofed.

Checkout Complete Details Here: https://prophecymarketinsights.com/market_insight/Global-Epigenetics-Market-By-Product-36

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

Browse Similar Reports:

World Deferiprone Market Size, Share, Growth Survey 2020 to 2030 and Industry Analysis Report

Porcine Reproductive Respiratory Syndrome Vaccines Market Research Report (2020-2030) | Demand, Growth, Opportunities 2030

Porcine Vaccines Market – Revenue, Opportunity, Segment and Key Trends 2020-2030

Read the original:
Global Epigenetics Market Perspective with Study of Leading Players and Revenue to Significant Growth Forecast by 2030 - Citi Blog News

MADRID, Spain and CAMBRIDGE, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces that its management will present recent progress of vafidemstat in central nervous system (CNS) indications at the 3rd Neuroscience Innovation Forum in San Francisco on January 12.

Vafidemstat is in Phase II clinical development in multiple trials. It has demonstrated promise as a safe, well-tolerated and differentiated therapeutic option for treating agitation and aggression, and for treating non-aggressive features of three distinct psychiatric diseases.

Oryzons CEO Dr. Carlos Buesa and CMO Dr. Roger Bullock will make the presentation at the Marines' Memorial Club, a day before the JP Morgan Healthcare Conference. Oryzons presentation will take place at 13:50 PT in Track E in the Room Commandants. At the same event, Dr. Buesa will also participate in the Advances in Alzheimers & Other Cognitive Disorders Panel discussion at 9:30 am PT.

Oryzon will also take part in the 9th Annual LifeSci Advisors Corporate Access Event from January 13 to January 15, 2020 where Oryzons CEO and other management will hold meetings with pharmaceutical companies, institutional investors, analysts and other members of the biotech community at the Sir Francis Drake Hotel (450 Powell Street).

About OryzonFounded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzons LSD1 program has rendered two compounds, vafidemstat and iadademstat, in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon has offices in Spain and the United States. For more information, visit http://www.oryzon.com.

About VafidemstatVafidemstat (ORY-2001) is an oral, CNS optimized LSD1 inhibitor. The molecule acts on several levels: it reduces cognitive impairment, including memory loss and neuroinflammation, and at the same time has neuroprotective effects. In animal studies vafidemstat not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice, a model for accelerated aging and Alzheimers disease (AD), to normal levels and also reduces social avoidance and enhances sociability in murine models. In addition, vafidemstat exhibits fast, strong and durable efficacy in several preclinical models of multiple sclerosis (MS). Oryzon has performed a Phase IIa clinical trial in aggressiveness in patients with different psychiatric disorders (REIMAGINE), with positive preliminary clinical results reported. Additional Phase IIa clinical trials with vafidemstat are ongoing in patients with Mild to Moderate AD (ETHERAL), in aggressiveness in patients with moderate or severe AD (REIMAGINE-AD), and in Relapse-Remitting and Secondary Progressive MS (SATEEN).

About IadademstatIadademstat (ORY-1001) is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers (See Maes et al., Cancer Cell 2018 Mar 12; 33 (3): 495-511.e12.doi: 10.1016 / j.ccell.2018.02.002.). A first Phase I/IIa clinical trial with iadademstat in refractory and relapsed acute leukemia patients demonstrated the safety and good tolerability of the drug and preliminary signs of antileukemic activity, including a CRi. Beyond hematological cancers, the inhibition of LSD1 has been proposed as a valid therapeutic approach in some solid tumors such as small cell lung cancer (SCLC), medulloblastoma and others. Oryzon is currently conducting two Phase IIa clinical trials of iadademstat in combination; the first one in combination with azacitidine in elderly AML patients (ALICE study) and the second one in combination with platinum/etoposide in second line SCLC patients (CLEPSIDRA study). In both studies, preliminary clinical results have been reported.

Story continues

FORWARD-LOOKING STATEMENTS This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words expects, anticipates, believes, intends, estimates and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisin Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forwardlooking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzons securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzons securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements.

See the original post here:
ORYZON to Present at the 3rd Neuroscience Innovation Forum in San Francisco - Yahoo Finance

HOUSTON, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers,today announced that it will host a key opinion leader (KOL) call on Epigenetics, Thursday, December 19th at 12pm Eastern Time.

The call will feature a presentation by KOLs Damon Reed, MD, Moffitt Cancer Center, and Johnathan Whetstine, PhD, Fox Chase Cancer Center, who will discuss Epigenetics, and how drugs that regulate gene expression (epigenetic drugs) are a viable strategy for treatment and management of cancer. They will also discuss recent clinical successes with epigenetic drugs, and what to expect from novel agents. Drs. Reed and Whetstine will be available to answer questions at the conclusion of the call.

The call will also feature a presentation by Salarius management team, which will provide an update on their lead program, Seclidemstat. Management will share the latest on their clinical program and on new areas of interest including immunotherapy and select tumor mutations. Seclidemstat, a reversible LSD1 inhibitor, inhibits LSD1s enzymatic and scaffolding properties, representing a viable therapeutic option for patients who need it the most.

Damon Reed, MD is the Director of the Adolescent and Young Adult Program at Moffitt Cancer Center, an Associate Member of the Sarcoma Department at Moffitt Cancer Center and an Assistant Professor of Pediatrics at the University of South Florida. He is also on staff as a specialty physician at All Childrens Hospital in St. Petersburg, FL. He is the Leader of the National Pediatric Cancer Foundations pediatric phase I consortium, the Sunshine Project. Dr. Reeds research interests include chemotherapeutic approaches to sarcoma in the pediatric and adolescent and young adult population. He is interested in establishing relevant preclinical sarcoma models, establishing and testing biomarkers for targeted therapies and translating predictive testing and combinations of agents towards personalized medicine in sarcoma and other rare cancers. A graduate of Case Western Reserve University School of Medicine in Cleveland, OH, Dr. Reed served a combined pediatric residency program at Boston Childrens Hospital-Harvard Medical School and Boston Medical Center-Boston University School of Medicine. He completed his fellowship training in pediatric hematology/oncology at St. Jude Childrens Research Hospital. Dr. Reed has received numerous academic awards, including graduating valedictorian from Canfield High School and summa cum laude from the University of Dayton. He received the CWRU Medical Alumni Association Board of Trustees Award for Outstanding Service and Contributions to the School of Medicine and was named to the Alpha Omega Alpha Honor Medical Society. Dr. Reed is a member of several professional associations, including the American Association for Cancer Research, Connective Tissue Oncology Society and American Society of Clinical Oncology. Dr. Reed is the Principal Investigator of Salariuss ongoing Ewing sarcoma Phase 1/2 clinical trial.

Johnathan Whetstine, PhD is the Program Leader of the Cancer Epigenetic Program at the Fox Chase Cancer Center. A rising star in the field of epigenetics, Dr. Whetstine has made groundbreaking discoveries that have expanded the field and provided significant implications for understanding tumor heterogeneity and drug response. In recognition of the promise of his research, he holds the prestigious Scholar award from the Leukemia & Lymphoma Society and a National Institutes of Health R01 grant, as well as funding from the American Lung Association, Alex Lemonade Stand Foundation and AstraZeneca. Recently, Dr. Whetstine helped coordinate the Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic, which brought together experts in the field of LSD1 research. Prior to Fox Chase, Dr. Whetstine was at Massachusetts General Hospital Cancer Center and Harvard Medical School in Boston, where he served as vice chair of the Epigenetics Program. He also held appointments as associate geneticist and associate professor in the department of medicine, respectively. He completed his postdoctoral fellowship in epigenetics/pathology in the laboratory of Yang Shi, PhD, at Harvard Medical School, and earned his PhD in pharmacology from Wayne State University in Detroit. Dr. Whetstine has served on Salariuss Advisory Board.

About Salarius Pharmaceuticals Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most. Epigenetics refers to the regulatory system that affects gene expression. In some cancers, epigenetic regulators often become dysregulated and incorrectly turn genes on or off leading to cancer progression. Drugs that can safely modify the activity of these epigenetic regulators may correct the gene changes that are driving the disease. The companys lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug designation and Rare Pediatric Disease Designation by the U.S. Food and Drug Administration. Salarius believes that Seclidemstat is one of only two reversible inhibitors of the epigenetic modulator LSD1 currently in human trials, and that it could have potential for improved safety and efficacy compared to other LSD1-targeted therapies. Salarius is also developing Seclidemstat for several cancers with high unmet medical need, with a second Phase 1 clinical study in advanced solid tumors, including prostate, breast and ovarian cancers. Salarius receives financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and is also the recipient of an $18.7 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as will, can, could, believe, feel, plan, allow, will, expect, provide, able to, position, anticipate, progress, potential, target, and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements regarding: the companys lead program, Seclidemstat, the companys clinical program and new areas of interest including immunotherapy and select tumor mutations; the potential for Seclidemstat as viable therapeutic option for patients who need it the most; the companys belief that Seclidemstat is one of only two reversible inhibitors of the epigenetic modulator LSD1 currently in human trials, and that it could have potential for improved safety and efficacy compared to other LSD1-targeted therapies; and the companys development of Seclidemstat for several cancers with high unmet medical need, with a second Phase 1 clinical study in advanced solid tumors, including prostate, breast and ovarian cancers. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the ability of the company to raise additional capital to meet the companys business operational needs and to achieve its business objectives and strategy; the companys ability to project future capital needs and cash utilization; available sources of cash, including from CPRIT and its equity line; future clinical trial results; that the results of studies and clinical trials may not be predictive of future clinical trial results; the sufficiency of Salarius intellectual property protection; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; market conditions which may impact the ability of Salarius access capital under its equity line; the possibility of unexpected expenses or other uses of Salarius cash resources; and other risks described in Salarius filings with the Securities and Exchange Commission, including those under the heading Risk Factors. The forward-looking statements contained in this press release speak only as of the date of this press release and are based on managements assumptions and estimates as of such date. Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.

ContactsInvestor Relations LifeSci Advisors, LLCJeremy FefferManaging Director(212) 915-2568 jeremy@lifesciadvisors.com

Media Relations:Tiberend Strategic Advisors, Inc.Johanna BennettSenior Vice President(212) 375-2686jbennett@tiberend.com

More:
Salarius Pharmaceuticals Hosting Key Opinion Leader Call on Epigenetics, The Regulatory System That Affects Gene Expression - BioSpace

In a recent study published by Prophecy Market Insights, titled, Global Epigenetics Market Research Report, analysts offers an in-depth analysis of global Epigenetics market. The study analyses the various aspect of the market by studying its historic and forecast data. The research report provides Porters five force model, SWOT analysis, and PESTEL analysis of the Epigenetics market. The different areas covered in the report are Epigenetics market size, drivers and restrains, segment analysis, geographic outlook, major manufacturers in the market, and competitive landscape.

Key Players of Epigenetics Market:

Illumina Inc., Thermo Fisher Scientific Inc., Merck Millipore Limited, Bio-Rad Laboratories, Inc., Qiagen Inc., Zymo Research Corporation, Diagenode s. a., Enzo Life Sciences, Inc. and New England Biolabs Inc.

Download Sample Copy of This Report @ https://prophecymarketinsights.com/market_insight/Insight/request-sample/36

The research report, Epigenetics Market presents an unbiased approach at understanding the market trends and dynamics. Analysts have studied the historical data pertaining to the market and compared it to the current market trends to paint an object picture of the markets trajectory. The report includes SWOT analysis and Porters five forces analysis to give the readers an in-depth assessment of the various factors likely to drive and restrain the overall market.

Market Segmentation:

Request PDF catalogue for this report @ https://prophecymarketinsights.com/market_insight/Insight/request-sample/36

Table of Contents

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the global Epigenetics market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the global Epigenetics market is analyzed, taking into consideration price, revenue, sales, and market share by company, market concentration rate, competitive situations and trends, expansion, merger and acquisition, and market shares of top 5 and 10 companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the global Epigenetics market as well as some useful information on their business. It talks about the gross margin, price, revenue, products and their specifications, applications, competitors, manufacturing base, and the main business of players operating in the global Epigenetics market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Epigenetics market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This part of the research study shows how different application segments contribute to the global Epigenetics market.

Market Forecast: Here, the report offers complete forecast of the global Epigenetics market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Upstream Raw Materials: The report provides analysis of key raw materials used in the global Epigenetics market, manufacturing cost structure, and the industrial chain.

Marketing Strategy Analysis and Distributors: This section offers analysis of marketing channel development trends, indirect marketing, and direct marketing followed by a broad discussion on distributors and downstream customers in the global Epigenetics market.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

Appendix: Here, we have provided a disclaimer, our data sources, data triangulation, market breakdown, research programs and design, and our research approach.

For More Info: https://prophecymarketinsights.com/market_insight/Global-Epigenetics-Market-By-Product-36

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

Browse Similar Reports:

Carbon Black Market Assessment On Competition 2020 – 2030

Activated Carbon Market to Reap Excessive Revenues by 2020 – 2030

Iron Powder Market Evolving Latest Trends to Lead Global Industry By 2020 – 2030

This post was originally published on Info Street Wire

Read the original:
Epigenetics Market: 2020 Industry Outlook, Comprehensive Insights, Growth and Forecast 2030 - Info Street Wire

One out of eight couples has trouble conceiving, with nearly a quarter of those cases caused by unexplained male infertility. For the past decade, research has linked that infertility to defective sperm that fail to evict proteins called histones from DNA during development. However, the mechanisms behind that eviction and where this is happening in the sperm DNA has remained both controversial and unclear.

Now, researchers atPenn Medicineshow, using newer genome-wide DNA sequencing tools, the precise genetic locations of those retained histones, as well as a key gene regulating it. The findings were published inDevelopmental Cell.

Taking it a step further, the researchers created a new mouse model with a mutated version of the gene,Gcn5, which allows investigators to closely track the defects in sperm from the early stages of sperm development through fertilization and on. This is an important step forward as it could lead to a better understanding of not only infertility in menand ways to potentially reverse itbut also the suspected epigenetic mutations being passed onto the embryo from males either naturally or through in vitro fertilization.

Epigenetics, the factors influencing an organisms genetics that are not encoded in the DNA, play a strong role in sperm and egg formation.

For men who have unexplained infertility, everything may look normal at the doctors: normal semen counts, normal motility. Yet they can still have problems conceiving, says first authorLacey J. Luense, a research associate in the lab of the study's senior author,Shelley L. Berger, the Daniel S. Och University Professor in the departments of Cell and Developmental Biology in the Perelman School of Medicine and Biology in the School of Arts and Sciences, and director of the Penn Epigenetics Institute. One explanation for persistent problems is histones being in the wrong location, which may affect sperm and then early development. Now, we have a really good model to study what happens when you dont get rid of the histones appropriately in the sperm and what that may look like in the embryo.

Read more at Penn Medicine News.

Originally posted here:
Uncovering a defective sperm epigenome that leads to male infertility - Penn: Office of University Communications

The UN Climate Change Conference in Madrid opened on December 2 by calling the climate crisis a war against nature. But trees have always been at war, fighting for their survival. While plants may seem passive in the environment, they can sense their environments, make decisions, and respond to threatsup to a point.

Every autumn holds terrible perils for plants. While many trees drop their leaves every year, the decision of precisely when to do so is a delicate one, as Peter Wohlleben, a German forest ranger, explains in The Hidden Life of Trees. Too soon and trees lose the chance to make food for the coming spring. Too late and an early snow or ice storm can weigh down leaves, tear off branches, and cause fatal injuries.

That decision may seem automatic to a human observer, but individual trees actually make different calls, which shows how subjective the event is. Wohlleben describes 300-year-old oak trees growing side by side. One always sheds its leaves earlier than the others. The timing of leaf drop, it seems, really is a question of character, he writes. The tree on the right is a bit more anxious than the others, or to put it more positively, more sensible. The two others are bolder, he writes, gambling on good weather.

Also Read: Science Isnt the Only Way to Look at a Tree. Marvelling Is Another.

Trees decide when to act based on day length and temperature, which they can easily sense. Rising temperatures mean spring; falling temperatures mean fall. And what this proves as well, Wollenben writes, is that trees must have a memory.

This is quite different from the detailed and emotion-filled memories we recall every day, writes biologist Daniel Chamovitz in the book What a Plant Knows. Yet plants use some of the same mechanisms we do to recall events. Epigenetics is one major way that past experiences stay with us, such as tolerance for cold climatesand with plants, too.

Trees decide when to act based on day length and temperature, which they can easily sense. Credit: Creative Commons

Epigenetic changes affect the way genes are expressed without altering the underlying DNA code. The DNA is wrapped around proteins called histones, Chamovitz writes, and events can change certain histones, which in turn affect which genes turn on or off. In that way, plants remember things like bad weather and attacks by insects. Furthermore, they not only remember environmental stress but they can pass those memories on, because epigenetic changes are heritable. Their seeds come prepared for the problems their parents encountered.

That means they can recognise droughts and recall ways to cope. Trees can prepare to close the pores (stomata) on their leaves to limit water loss or grow fewer stomata, and can be ready to bring up more water from their roots. With something called somatic adaptation, the growing tips of branches can use a different phenotypethat is, change their actual physical formto cope with new anticipated growing conditions. This lets trees survive a wide range of environments. Trees, though we think of them as stationary and static, can use electrochemical gradients to move, as a Venus flytrap closes when an insect touches certain hairs in its trap. These gradients work like the electric signals in our nervous system.

But instead of a nervous system, any centralised source of decision-making, plants have what plant neurobiologist Stefano Mancuso, in The Revolutionary Genius of Plants, calls collective intelligence. Each part reacts to changes in its environment, including the changes in neighbouring parts of its own organism, much like a colony of bees. Even though they have nothing akin to a central brain, Mancuso writes, plants exhibit unmistakable attributes of intelligence. They are able to perceive their surroundings with a greater sensitivity than animals do.

Chamovitz writes, intelligence is a loaded term, but plants are acutely aware of the world around them. They can sense different kinds of light, evaluate chemicals in the air including those emitted by other plants, distinguish different kinds of touches to their leaves, and locate gravity. And plants are aware of their past. They dont know us as individuals, but they know their environment, and people are part of this environment.

What they may not realise is how dramatically the human part of their environment is altering the rest. Winter comes later, spring comes earlier, storms come more erratically and cause more damage. Summers are hotter, and droughts occur more often and are more severe.

Also Read: How I Became a Tree is an Ode to All That is Neglected

Trees know how to adapt, but there is a limit, says Andrew Mathews, a professor of environmental anthropology at the University of CaliforniaSanta Cruz. His work emphasises forestry and sustainability. In Europe, the last ice age ended about 12,000 years ago, which is only 20 generations for trees, he says, so adult trees are out of sync anyway with the climate, but thats not their most immediate problem.

Trees dont live in climate. They live in weather, he says, and they can adjust several times in a lifetime to cope in ways that animals cant, dropping leaves earlier or later, changing the shape and texture of their leaves, altering structures in their trunks, or growing deeper or shallower roots. Trees can even migrate to better climate zones by sending seeds carried by winds or animals to sprout in new areas. But can they move fast enough? Even if they do, new habitats are limited. Trees in mountainous areas can migrate to higher latitudes as temperatures rise, but even if they move fast enough, they may be pushed upslope until they have nowhere else to go and will become extinct in that location, Mathews says.

Trees in mountainous areas can migrate to higher latitudes as temperatures rise. Photo: Samuel Ferrara/Unsplash

Even if plants do succeed in adapting to climate change by changing their location or schedule, theyre not alone in their biospheres. The flowers they may decide bloom earlier or later need pollinators. Will the bees, birds, butterflies, wasps, spiders, and flies move in tandem with the trees, and if they do, will they be on the same schedule? Scientists just dont know.

We can debate the definition of intelligence, but we know that trees can identify and solve problems in ways that we cant. They remember that spring is coming, and when it does theyll be ready to sense the weather and make their decisions in response. But what they dont know is that their decisions become more critical with every passing season and year. Our decisions are just as critical. But we know that we can foresee the futureand as smart as they are, the trees cant.

This piece was originally publishedonFutureTense, a partnership betweenSlatemagazine, Arizona State University, and New America.

Read the original here:
Trees of Knowledge - The Wire

CMI published a business research report on Epigenetics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 20182026. Epigenetics Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The information is gathered based on modern floats and requests identified with the administrations and items.

Click To Get Free PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1772

The worldwide Epigenetics Market report stresses the most recent advancements, development, new chances, and lethargic traps. It gives a comprehensive position of the worldwide Epigenetics Market. The Epigenetics Market research report covers the present scenario and the growth prospects of the global Epigenetics Market industry for 2018-2026. The report enlists several important factors, starting from the basics to advanced market intelligence which play a crucial part in strategizing. Epigenetics Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Epigenetics Market industry.

Leading Market Player Profile Included in This Report is: Illumina Inc., Thermo Fisher Scientific Inc., Merck Millipore Limited, Bio-Rad Laboratories, Inc., Qiagen Inc., Zymo Research Corporation, Diagenode s. a., Enzo Life Sciences, Inc. and New England Biolabs Inc.

Most of the information assembled is exhibited in a graphical frame alongside the related measurements. The Epigenetics Market report exhibits the working of the fundamental market players, providers, and merchants in detail. The report likewise features the limitations and drivers affecting the Epigenetics Market.

The report likewise incorporates a fundamental profile and data of all the significant market players at present dynamic in the worldwide Epigenetics Market. The organizations canvassed in the report can be assessed based on their most recent advancements, monetary and business diagram, item portfolio, enter drifts in the market, long haul and here and now business methodologies by the organizations with the end goal to remain aggressive in the market.

Get Sample Copy with Graphs and Charts @ https://www.coherentmarketinsights.com/insight/request-sample/1772

Important Features of the Keword Market:

To build up a far-reaching, verifiable, every year refreshed and financially savvy data dependent on execution, capacities, objectives, and systems of the worlds driving organizations.

To help current providers reasonably evaluate their money related, advertising and innovative capacities opposite driving contenders.

To help potential market contestants in assessing imminent acquisitions and joint endeavor hopefuls.

To supplement associations inner rival data gathering endeavors by giving vital investigation, information understanding, and knowledge.

To distinguish the slightest focused market specialties with huge development potential.

Global Epigenetics Market: Regional Segment Analysis

North America (U.S., Canada, Mexico),

Europe (Germany, U.K., France, Italy, Russia, Spain etc),

South America (Brazil, Argentina etc)

Middle East & Africa (Saudi Arabia, South Africa etc).

Asia-Pacific (China, Japan, India)

In order to get a deeper view of Market Size, competitive landscape is provided i.e. Revenue (Million USD) by Players (2013-2018), Revenue Market Share (%) by Players (2013-2018) and further a qualitative analysis is made towards market concentration rate, product/service differences, new entrants and the technological trends in future.

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/1772

Available Customizations

As per specific needs customizations of the given market data is also available. Talk to our research consultant to design an exclusive report as per your research needs like Regional and country-level analysis of market by end-use, detailed analysis and profiles of additional market players.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Phone: US +12067016702 / UK +4402081334027

Email: [emailprotected]

Visit This Blog: http://bit.ly/Rajkumar123

Go here to read the rest:
Epigenetics Market by Applications, Vertical Type, and by Regions, 20162026 (US$ Million) - Market Reports Observer

HOUSTON, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer, announced today the acceptance of an abstract at the Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic taking place Monday, December 16, 2019 at the Franklin Institute in Philadelphia, PA. The trial-in-progress poster presentation will include an overview of the ongoing Phase 1/2 clinical trial for Salarius lead drug candidate, Seclidemstat, a potent reversible LSD1 inhibitor being developed as a treatment for Ewing sarcoma, a rare pediatric bone cancer.

Details of the symposium and poster presentation are as follows:

Abstract Title: Trials in progress: A phase I/II clinical trial of the reversible LSD1 inhibitor, seclidemstat, in patients with relapsed/refractory Ewing sarcomaWhere: The Franklin Institute, 222 North 20th Street, PhiladelphiaWhen: Monday, December 16, 2019 at 8:30 a.m. EST to 7 p.m. ESTSymposium Website: Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic

The Epigenetics Symposium is an ideal event to showcase our progress bringing our lead drug candidate, Seclidemstat, into the clinic and the impact it could have on Ewing sarcoma, a rare and deadly bone cancer that most often strikes children and young adults and for which there are no targeted therapies approved, stated David Arthur, Chief Executive Officer of Salarius Pharmaceuticals. Lysine demethylase enzymes are a well-known target for epigenetic-based drug development. We have developed Seclidemstat to be a differentiated LSD1 inhibitor, and we are excited that it has reached the clinical trial setting where its safety and therapeutic activity can be assessed. Research shows that LSD1 expression is elevated in 60% of Ewing sarcoma patients and correlates with poor patient prognosis and decreased overall survival. Given the potential of Seclidemstat to address this great unmet need, we look forward to releasing early cohort data next year from our Ewing sarcoma study and a Phase 1 study in advanced solid tumors.

About Salarius PharmaceuticalsSalarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most. Epigenetics refers to the regulatory system that affects gene expression. In some cancers, epigenetic regulators often become dysregulated and incorrectly turn genes on or off leading to cancer progression. Drugs that can safely modify the activity of these epigenetic regulators may correct the gene changes that are driving the disease. The companys lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug designation and Rare Pediatric Disease designation by the U.S. Food and Drug Administration. Salarius believes that Seclidemstat is one of only two reversible inhibitors of the epigenetic modulator LSD1 currently in human trials, and that it could have potential for improved safety and efficacy compared to other LSD1-targeted therapies. Salarius is also developing Seclidemstat for several cancers with high unmet medical need, with a second Phase 1 clinical study in advanced solid tumors, including prostate, breast and ovarian cancers. Salarius receives financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and is also the recipient of an $18.7 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as will, can, could, believe, plan, allow, expect, provide, able to, position, anticipate, progress, potential, and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements regarding: the progress in bringing Seclidemstat into the clinic and the impact it could have on Ewing sarcoma; the development of Seclidemstat to be a differentiated LSD1 inhibitor; the potential of Seclidemstat; anticipated timing of release of early cohort data from the companys Ewing sarcoma study and a Phase 1 study in advanced solid tumors; the companys belief that Seclidemstat is one of only two reversible inhibitors of LSD1 currently in human trials and that it could have potential for improved safety and efficacy compared to other LSD1-targeted therapies; and the companys development of Seclidemstat for several cancers with high unmet medical need, including prostate, breast and ovarian cancers. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the ability of the company to raise additional capital to meet the companys business operational needs and to achieve its business objectives and strategy; the companys ability to project future capital needs and cash utilization; available sources of cash, including from CPRIT and its equity line; future clinical trial results; that the results of studies and clinical trials may not be predictive of future clinical trial results; the sufficiency of Salarius intellectual property protection; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; market conditions which may impact the ability of Salarius to access capital under its equity line; the possibility of unexpected expenses or other uses of Salarius cash resources; and other risks described in Salarius filings with the Securities and Exchange Commission, including those under the heading Risk Factors. The forward-looking statements contained in this press release speak only as of the date of this press release and are based on managements assumptions and estimates as of such date. Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.

Contacts Investor Relations LifeSci Advisors, LLCJeremy FefferManaging Director(212) 915-2568 jeremy@lifesciadvisors.com

Media Relations: Tiberend Strategic Advisors, Inc.Johanna BennettSenior Vice President (212) 375-2686 jbennett@tiberend.com

Go here to read the rest:
Salarius Pharmaceuticals to Present Trial-in-Progress Poster at Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic -...

Epigenetics Market research now available at Brand Essence Research encompasses an exhaustive Study of this business space with regards to pivotal industry drivers, market share analysis, and the latest trends characterizing the Epigenetics industry landscape. This report also covers details of market size, growth spectrum, and the competitive scenario of Epigenetics market in the forecast timeline.

The Epigenetics Market Report provides key strategies followed by leading Epigenetics industry manufactures and Sections of Market like- product specifications, volume, production value, Feasibility Analysis, Classification based on types and end user application areas with geographic growth and upcoming advancement. The Epigenetics market report provides comprehensive outline of Invention, Industry Requirement, technology and production analysis considering major factors such as Revenue, investments and business growth.

Request for Sample of this Report@ https://brandessenceresearch.biz/Request/Sample?ResearchPostId=68491&RequestType=Sample

The well-established players in the market are:

This report for Epigenetics Market discovers diverse topics such as regional market scope, product market various applications, market size according to specific product, sales and revenue by region, manufacturing cost analysis, Industrial Chain, Market Effect Factors Analysis, market size forecast, and more.

Drivers & Hindrances of the Epigenetics market: How does the report explicate on the same

The report unveils the driving parameters affecting the commercialization chart of this industry.

The Epigenetics market research report further illustrates the various challenges that this market is prone to as well as its impact on the market trends.

An important aspect that the report sets focus on is the market concentration ratio for the predicted timeframe.

The geographical spectrum of the business and its consequence on the Epigenetics market:

The report segments the Epigenetics market into USA, Europe, Japan, China, India, South East Asia depending on the regional scope of this business

Extensive data about the product consumption across innumerable sections as well as the valuation developed by these regions is also explained in the report.

The study puts emphasis on data concerning the consumption market share across these regions, as well as the market share attained by every region and product consumption growth rate.

Market segment by Type, the product can be split into

Market segment by Application, split into

Market segment by Regions/Countries, this report covers

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

Request Customization of this Report: https://brandessenceresearch.biz/Request/Sample?ResearchPostId=68491&RequestType=Methodology

Key highlights and essential features of the report:

1) Which major players are presently listed in the report?Here are the companies that are presently listed in the report: Abcam Plc., Illumina, QIAGEN N.V., Merck & Co., New England Biolabs, Inc., Epizyme Inc., Thermo Fisher Scientific, Inc., Active Motif. Diagenode, Inc., and Zymo Research Corporation others.

**List of the firms stated above might differ in the final report dependent on a merger, name change, and other factors.

2) Can you list or add new firms as per our requirement?Yes,we can list or add new firm as per the requirement by client in the report. The final confirmation regarding the same must be provided by the research team subject to difficulty of survey.

**Availability of data will be confirmed after research in case of a privately held firm. Maximum 3 companies can be included at no additional charge.

3) Which all regional categorization are covered? Is it possible to add any specific country?Presently, our research report offers special focus and attention on the following areas:Europe, United States, Japan, China, India, Southeast Asia, and Central & South America

**Maximum one country of specific interest can be added at no extra charge. Charges will be applied for the addition of extra countries or regions.

4) Can the addition of extra Market breakdown or segmentation is possible?Yes, the addition of extra Market breakdown or segmentation is possibly dependent on the difficulty of survey and availability of data. On the other hand, detailed sharing of the requirements with our research team is a must before providing final confirmation to the client.

More Details on this Report: https://brandessenceresearch.biz/Request/Sample?ResearchPostId=68491&RequestType=Customization

Table of Content:

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Epigenetics Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Epigenetics Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Epigenetics Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Epigenetics Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Epigenetics Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Epigenetics Market.

Market Forecast:Here, the report offers a complete forecast of the global Epigenetics Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

Appendix:Here, we have provided a disclaimer, our data sources, data triangulation, research programs, market breakdown and design, and our research approach.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Contact US:

https://brandessenceresearch.biz/

Brandessence Market Research & Consulting Pvt ltd.

Kemp House, 152 160 City Road, London EC1V 2NX

+44-2038074155

sales@brandessenceresearch.com

View post:
Epigenetics Market Size Analysis, Application Analysis, Regional Outlook, Competitive Strategies and Forecasts, 2019 To 2025 - The Market Stats News